Pegvisomant therapy in acromegalic patient resistant to other treatment: case report
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.010Keywords
Acromegaly, treatment, pegvisomant, pituitary macroadenomaAbstract
Introduction: Acromegaly is a chronic, rare disorder resulting from growth hormone (GH) hypersecretion, usually caused by a pituitary adenoma. GH stimulates synthesis of insulin-like growth factor 1 (IGF-1), whom assay should be used as a screening test whenever acromegaly is suspected. Patients with acromegaly normally take from 5 to 10 years to receive a correct diagnosis, leading to complications such as cardiovascuar, respiratory, and endocrine problems that are responsible for an increase mortality. Late diagnosis of the disease also impact the effectiveness of surgical, pharmacological and radiotherapy treatment.
Case report: A 33-year-old acromegalic man with pituitary macroadenoma resistant to therapy of somastatin analogue (octreotide, lanreotide) and dopamine agonist (cabergoline). The patient underwent transsphenoidal adenomectomy, after wich high level of GH and IGF-1 were still measured. Due to the lack of the effect of the current treatment, the patient was qualified for pegvisomant therapy, as a result of which biochemical control was achieved without adverse events and with a good compliance of treatment.
Conclusions: Treatment with pegvisomant is now an important therapeutic strategy to achieve full disease control in acromegalic patients resistant or poorly responders to first generation somatostatin receptor ligands and in patients who do not respond adequately to selective excision of pituitary adenoma and /or for whom surgery is not possible.
References
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–351. doi: 10.1210/jc.2014-2700
Melmed S. Medical progress: acromegaly. N Engl J Med. 2006; 355(24): 2558–2573, doi:10.1056/NEJMra062453.
Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4-9. doi:10.1007/s11102-016-0754-x
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004 Feb;25(1):102-52. doi: 10.1210/er.2002-0022.
Bolanowski M, Ruchała M, Zgliczyński W, Kos-Kudła B, Bałdys-Waligórska A, Zieliński G, Bednarczuk T, Hubalewska-Dydejczyk A, Kamiński G, Marek B, Daroszewski J, Waśko R, Lewiński A. Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports. Endokrynol Pol. 2014;65(4):326-31. doi: 10.5603/EP.2014.0045.
Giustina A, Chanson P, Kleinberg D, et al. Acromegaly Consensus Group. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014; 10(4): 243–248, doi: 10.1038/nren- do.2014.21
Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A. Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother. 2016 Aug;17(12):1631-42. doi: 10.1080/14656566.2016.1199687
Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resis- tance to treatment in pituitary adenomas. J Mol Endocrinol. 2014; 52(3): R223–R240, doi: 10.1530/JME-14-001
Andersen M. Management of endocrine disease: GH excess: diagnosis and medical therapy. Eur J Endocrinol 2014; 170: R31–R41.
Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, et al. Pegvisomant in acromegaly: an update. J Endocrinol Investig. 2017;40(6): 577–89.
Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009 May;94(5):1509-17. doi: 10.1210/jc.2008-2421.
Barraud S, Caron P, Raingeard I, Lefebvre H, Raverot G, Cortet-Rudelli C, Desailloud R, Henocque R, Brault Y, Brue T, Chanson P, Delemer B. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients). Ann Endocrinol (Paris).2021Dec;82(6):582-589.doi:10.1016/j.ando.2021.05.004.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Emilia Nowicka, Michał Obel, Piotr Dzikowski, Martyna Stefaniak, Zofia Pietrzak, Ewa Obel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 461
Number of citations: 0